ANCA相关性血管炎 中国就医指南

ANCA-associated vasculitis (AAV) is a group of rare, systemic autoimmune disorders characterized by inflammation and necrosis of small- to medium-sized blood vessels, primarily driven by autoantibodies against neutrophil cytoplasmic antigens (ANCAs). The three main clinical entities under this umbrella are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These diseases predominantly affect the kidneys, lungs, upper airways, skin, nerves, and joints. Pathogenesis centers on dysregulated neutrophil activation: ANCAs—most commonly targeting proteinase 3 (PR3-ANCA in GPA) or myeloperoxidase (MPO-ANCA in MPA and EGPA)—bind to primed neutrophils, triggering uncontrolled degranulation, reactive oxygen species release, and endothelial injury. This cascade leads to pauci-immune necrotizing glomerulonephritis (a hallmark renal lesion), pulmonary capillaritis, and granulomatous inflammation in GPA. Genetic susceptibility (e.g., HLA-DQ variants, PRTN3 polymorphisms), environmental triggers (e.g., silica exposure, chronic nasal Staphylococcus aureus colonization, certain drugs like hydralazine or propylthiouracil), and epigenetic dysregulation contribute to disease onset. Epidemiologically, AAV affects approximately 10–20 new cases per million people annually worldwide, with prevalence estimated at 50–250 per million. Incidence rises sharply after age 50, peaking in the seventh decade; males and females are equally affected overall, though GPA shows slight male predominance. In China, AAV is increasingly recognized but likely underdiagnosed due to nonspecific early symptoms and limited ANCA testing access outside major centers. Key risk factors include older age, chronic sinusitis or asthma (especially in EGPA), occupational silica exposure, smoking, and certain infections. Renal involvement—present in up to 80% of GPA and MPA cases—often manifests as rapidly progressive glomerulonephritis (RPGN), leading to acute kidney injury and, if untreated, end-stage kidney disease requiring dialysis or transplantation. Beyond renal morbidity, patients frequently experience debilitating fatigue, arthralgias, neuropathy, pulmonary hemorrhage, and persistent upper respiratory tract damage. Quality of life is profoundly impacted: over 60% report moderate-to-severe impairment in physical functioning, role limitations, and mental health; depression and anxiety rates exceed population norms by 3–4 fold. Chronic immunosuppression increases infection risk and long-term cardiovascular morbidity, while treatment-related side effects—including osteoporosis, diabetes, cataracts, and malignancy—further erode well-being. Early diagnosis via ANCA serology (ELISA + IIF), renal biopsy (showing pauci-immune crescentic GN), and imaging (e.g., CT chest/sinus) is critical. Delayed recognition remains common, contributing to irreversible organ damage and higher mortality—5-year survival ranges from 70% to 85%, heavily dependent on timely intervention and sustained remission maintenance.

# ANCA相关性血管炎（肾内科）治疗方案与费用明细

一、非手术/药物治疗方案

• •诱导缓解期（活动性肾小球肾炎/肺泡出血）：

- 费用区间：¥12,000–¥38,000/疗程（含激素、环磷酰胺药费及住院管理）；利妥昔单抗方案：¥28,000–¥45,000/疗程（国产 vs 进口）。

• •维持治疗期（缓解后≥6个月）：

- 年均药费：¥6,000–¥22,000。

• •*配套检查费*（首诊+每月随访）：ANCA定量、肌酐、尿常规、24h尿蛋白、肾脏超声、胸部CT：¥1,800–¥3,200/次。

二、介入/核心治疗方案

• •血浆置换（PE）：适用于重症肺肾综合征（Scr >300 μmol/L 或弥漫性肺泡出血）；

- *术前检查*（凝血功能、肝肾功、中心静脉置管评估）：¥1,200–¥1,800。

三、特殊复杂方案

• •难治/复发/耐药患者：联合小剂量环孢素A或贝利尤单抗（超适应证）；年均费用：¥55,000–¥98,000；
• •终末期肾病（ESRD）合并血管炎活动：需透析+免疫抑制强化，年综合成本（含HD/腹透+药物+监测）：¥120,000–¥220,000。

四、方案快速选择指南

• •预算有限/初发轻症：环磷酰胺+激素方案（¥1.5万起）；
• •中重度肾损/高复发风险：利妥昔单抗诱导+硫唑嘌呤维持（¥5–8万/年）；
• •急进性肺肾综合征：立即启动血浆置换+利妥昔单抗（首月投入≥¥8万）。